Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Launched by PALO ALTO MEDICAL FOUNDATION · Aug 30, 2001
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following conditions are excluded:
- • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.
- • Patients with other opportunistic infections or brain diseases are excluded.
- • Patients with AIDS and cerebral toxoplasmosis.
About Palo Alto Medical Foundation
Palo Alto Medical Foundation (PAMF) is a leading healthcare organization dedicated to advancing medical research and improving patient care through innovative clinical trials. As a part of the Sutter Health network, PAMF combines cutting-edge technology with a patient-centered approach to deliver high-quality, evidence-based treatments. The foundation is committed to fostering collaboration among healthcare professionals and researchers, ensuring rigorous adherence to ethical standards and regulatory requirements. Through its diverse clinical trial portfolio, PAMF aims to contribute to medical knowledge and enhance therapeutic options for patients across a wide range of conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials